FR06C0021I2 - VASCULAR ENDOTHELIAL GROWTH FACTOR NUCLEIC ACID LIGAND COMPLEXES - Google Patents
VASCULAR ENDOTHELIAL GROWTH FACTOR NUCLEIC ACID LIGAND COMPLEXESInfo
- Publication number
- FR06C0021I2 FR06C0021I2 FR06C0021C FR06C0021C FR06C0021I2 FR 06C0021 I2 FR06C0021 I2 FR 06C0021I2 FR 06C0021 C FR06C0021 C FR 06C0021C FR 06C0021 C FR06C0021 C FR 06C0021C FR 06C0021 I2 FR06C0021 I2 FR 06C0021I2
- Authority
- FR
- France
- Prior art keywords
- nucleic acid
- acid ligand
- growth factor
- vascular endothelial
- endothelial growth
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
- A61K47/544—Phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3515—Lipophilic moiety, e.g. cholesterol
Abstract
This invention discloses a method for preparing a complex comprised of a VEGF Nucleic Acid Ligand and a Non-Immunogenic, High Molecular Weight Compound or Lipophilic Compound by identifying a VEGF Nucleic Acid Ligand by SELEX methodology and associating the VEGF Nucleic Acid Ligand with a Non-Immunogenic, High Molecular Weight Compound or Lipophilic Compound. The invention further discloses Complexes comprising one or more VEGF Nucleic Acid Ligands in association with a Non-Immunogenic, High Molecular Weight Compound or Lipophilic Compound. The invention further includes a Lipid construct comprising a VEGF Nucleic Acid Ligand or Complex and methods for making the same.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/739,109 US5859228A (en) | 1995-05-04 | 1996-10-25 | Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes |
US08/870,930 US6168778B1 (en) | 1990-06-11 | 1997-06-06 | Vascular endothelial growth factor (VEGF) Nucleic Acid Ligand Complexes |
US08/897,351 US6051698A (en) | 1997-06-06 | 1997-07-21 | Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes |
PCT/US1997/018944 WO1998018480A1 (en) | 1996-10-25 | 1997-10-17 | Vascular endothelial growth factor (vegf) nucleic acid ligand complexes |
Publications (2)
Publication Number | Publication Date |
---|---|
FR06C0021I1 FR06C0021I1 (en) | 2006-10-13 |
FR06C0021I2 true FR06C0021I2 (en) | 2007-08-03 |
Family
ID=27419245
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FR06C0021C Active FR06C0021I2 (en) | 1996-10-25 | 2006-07-03 | VASCULAR ENDOTHELIAL GROWTH FACTOR NUCLEIC ACID LIGAND COMPLEXES |
Country Status (18)
Country | Link |
---|---|
EP (2) | EP0957929B1 (en) |
JP (2) | JP3626503B2 (en) |
KR (1) | KR100514929B1 (en) |
AT (1) | ATE318143T1 (en) |
AU (1) | AU733674B2 (en) |
CA (1) | CA2269072C (en) |
DE (3) | DE122006000029I2 (en) |
DK (1) | DK0957929T3 (en) |
ES (1) | ES2259188T3 (en) |
FR (1) | FR06C0021I2 (en) |
GE (1) | GEP20094799B (en) |
IL (2) | IL129497A0 (en) |
LU (1) | LU91252I2 (en) |
NL (1) | NL300234I2 (en) |
NZ (1) | NZ334859A (en) |
PT (1) | PT957929E (en) |
RU (1) | RU2177950C2 (en) |
WO (1) | WO1998018480A1 (en) |
Families Citing this family (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6232071B1 (en) * | 1990-06-11 | 2001-05-15 | Gilead Sciences, Inc. | Tenascin-C nucleic acid ligands |
US6346611B1 (en) * | 1990-06-11 | 2002-02-12 | Gilead Sciences, Inc. | High affinity TGfβ nucleic acid ligands and inhibitors |
US6395888B1 (en) | 1996-02-01 | 2002-05-28 | Gilead Sciences, Inc. | High affinity nucleic acid ligands of complement system proteins |
US6762290B1 (en) * | 1999-07-29 | 2004-07-13 | Gilead Sciences, Inc. | High affinity vascular endothelial growth factor (VEGF) receptor nucleic acid ligands and inhibitors |
AU782620B2 (en) * | 1991-06-10 | 2005-08-11 | Gilead Sciences, Inc. | High affinity vascular endothelial growth factor (VEGF) receptor nucleic acid ligands and inhibitors |
HUP0202177A3 (en) * | 1999-07-14 | 2004-05-28 | Alza Corp Mountain View | Neutral lipopolymer and liposomal compositions containing same |
EP2351855A1 (en) * | 2000-09-26 | 2011-08-03 | Duke University | RNA aptamers and methods for identifying the same |
EP2431377B1 (en) * | 2001-10-26 | 2017-04-19 | Noxxon Pharma AG | Modified L-nucleic acids |
RS35404A (en) * | 2001-11-09 | 2006-10-27 | Eyetech Pharmaceuticals | Methods for treating ocular neovascular diseases |
US7767803B2 (en) | 2002-06-18 | 2010-08-03 | Archemix Corp. | Stabilized aptamers to PSMA and their use as prostate cancer therapeutics |
JP2005533862A (en) | 2002-07-25 | 2005-11-10 | アーケミックス コーポレイション | Modulated aptamer therapeutics |
US9303262B2 (en) | 2002-09-17 | 2016-04-05 | Archemix Llc | Methods for identifying aptamer regulators |
US10100316B2 (en) | 2002-11-21 | 2018-10-16 | Archemix Llc | Aptamers comprising CPG motifs |
US8853376B2 (en) | 2002-11-21 | 2014-10-07 | Archemix Llc | Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics |
US8039443B2 (en) | 2002-11-21 | 2011-10-18 | Archemix Corporation | Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics |
AU2003297682A1 (en) * | 2002-12-03 | 2004-06-23 | Archemix Corporation | Method for in vitro selection of 2'-substituted nucleic acids |
FR2852606A1 (en) * | 2003-03-18 | 2004-09-24 | Inst Nat Sante Rech Med | In vitro method for simultaneous inhibition of several genes, useful for treating cancer or viral infection, using a ligand that binds to a common site in the genes and induces cutting by topoisomerase |
EP1620547B1 (en) | 2003-04-21 | 2014-06-18 | Archemix LLC | Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics |
CL2004001996A1 (en) * | 2003-08-08 | 2005-05-06 | Eyetech Pharmaceuticals Inc | ANTI-VEGF APTAMEROS (VASCULAR ENDOTELIAL GROWTH FACTOR) WITH 5'-5 'OR 3'-3' INVERTED NUCLEOTIDIC BLOCK, COMPOSITION CONTAINING IT, USEFUL FOR NEOVASCULARIZATION DISORDERS. |
EP1727567B1 (en) | 2004-02-12 | 2013-07-03 | Archemix LLC | Aptamer therapeutics useful in the treatment of complement-related disorders |
US7803931B2 (en) | 2004-02-12 | 2010-09-28 | Archemix Corp. | Aptamer therapeutics useful in the treatment of complement-related disorders |
CA2562948A1 (en) * | 2004-04-13 | 2005-11-24 | (Osi) Eyetech, Inc. | Enhanced biologically active conjugates |
US7579450B2 (en) | 2004-04-26 | 2009-08-25 | Archemix Corp. | Nucleic acid ligands specific to immunoglobulin E and their use as atopic disease therapeutics |
EP2436391A3 (en) | 2004-11-02 | 2012-07-04 | Archemix LLC | Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics |
AU2006265896B2 (en) | 2005-06-30 | 2012-05-31 | Archemix Corp. | Materials and methods for the generation of fully 2'-modified nucleic acid transcripts |
US8101385B2 (en) | 2005-06-30 | 2012-01-24 | Archemix Corp. | Materials and methods for the generation of transcripts comprising modified nucleotides |
JP2009510182A (en) * | 2005-07-28 | 2009-03-12 | (オーエスアイ)アイテツク・インコーポレーテツド | Cycitol linker polymer conjugate |
CN101304748A (en) | 2005-08-22 | 2008-11-12 | 加利福尼亚大学董事会 | Tlr agonists |
KR100877824B1 (en) | 2005-11-11 | 2009-01-12 | 한국생명공학연구원 | E2EPF ubiquitin carrier protein-von Hippel-Lindau interaction and uses of thereof |
BRPI0619463A2 (en) * | 2005-12-06 | 2013-01-08 | Domantis Ltd | binding, use thereof, methods for treating cancer and for administering anti-vegf and anti-egfr treatment to an individual, composition, drug dispensing device, isolated or recombinant nucleic acid, vector, host cell, method for producing a ligand, immunoglobulin single variable domain polypeptide, and egfr antagonist |
EP1968643A2 (en) * | 2005-12-16 | 2008-09-17 | Diatos | Cell penetrating peptide conjugates for delivering of nucleic acids into a cell |
US20090175930A1 (en) * | 2006-01-11 | 2009-07-09 | Nobuhiro Yagi | Composition Suppressing The Expression of Target Gene in Eyeball and Medicament For Treating of Disease in Eyeball |
KR20150017388A (en) | 2006-03-08 | 2015-02-16 | 아케믹스 엘엘씨 | Complement binding aptamers and anti-c5 agents useful in the treatment of ocular disorders |
EA019151B1 (en) * | 2007-02-07 | 2014-01-30 | Дзе Регентс Оф Дзе Юниверсити Оф Калифорния | Conjugates of synthetic tlr agonists and uses thereof |
US20110229498A1 (en) | 2008-05-08 | 2011-09-22 | The Johns Hopkins University | Compositions and methods for modulating an immune response |
ES2600781T3 (en) * | 2008-12-04 | 2017-02-10 | Curna, Inc. | Treatment for diseases related to vascular endothelial growth factor (vegf) by inhibiting natural antisense transcripts of vegf |
PT2414322T (en) | 2009-03-20 | 2022-12-07 | Egen Inc | Polyamine derivatives |
WO2011061351A1 (en) | 2009-11-23 | 2011-05-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Aptamers directed against the matrix protein-1 of type a influenza viruses and uses thereof |
AR081361A1 (en) | 2010-04-30 | 2012-08-29 | Molecular Partners Ag | MODIFIED UNION PROTEINS THAT INHIBIT THE RECEPTOR INTERACTION OF THE VASCULAR ENDOTELIAL GROWTH FACTOR FROM GLICOPROTEIN TO VEGF-A |
KR20130136983A (en) * | 2010-09-24 | 2013-12-13 | 말린크로트 엘엘씨 | Aptamer conjugates for targeting of therapeutic and/or diagnostic nanocarriers |
US20150337308A1 (en) | 2012-04-11 | 2015-11-26 | Chu De Bordeaux | Matrix metalloproteinase 9 (mmp-9) aptamer and uses thereof |
US10942184B2 (en) | 2012-10-23 | 2021-03-09 | Caris Science, Inc. | Aptamers and uses thereof |
EP4170031A1 (en) | 2012-10-23 | 2023-04-26 | Caris Science, Inc. | Aptamers and uses thereof |
EP2935628B1 (en) | 2012-12-19 | 2018-03-21 | Caris Life Sciences Switzerland Holdings GmbH | Compositions and methods for aptamer screening |
KR101807590B1 (en) | 2013-03-22 | 2017-12-11 | 고쿠리츠다이가쿠호징 도쿄다이가쿠 | Aptamer to il-17 and use thereof |
KR20230152151A (en) | 2013-07-12 | 2023-11-02 | 이베릭 바이오, 인크. | Methods for treating or preventing ophthalmological conditions |
BR112016004153A2 (en) | 2013-08-28 | 2019-09-17 | Caris Life Sciences Switzerland Holdings Gmbh | "method for characterizing a disease or disorder, kit, composition, method for generating an input library, oligonucleotide, plurality of oligonucleotides and method for identifying an aptamer |
CN112826934A (en) | 2014-12-11 | 2021-05-25 | 拜耳医药保健有限责任公司 | Treatment of age-related macular degeneration with small active choroidal neovascularisation |
CA2971830A1 (en) | 2014-12-29 | 2016-07-07 | Bonac Corporation | Composition containing nucleic acid molecule stably |
US20180066262A1 (en) | 2015-03-09 | 2018-03-08 | Caris Science, Inc. | Oligonucleotide probes and uses thereof |
AU2016287499B2 (en) | 2015-06-29 | 2022-08-04 | Caris Science, Inc. | Therapeutic oligonucleotides |
US10941176B2 (en) | 2015-07-28 | 2021-03-09 | Caris Science, Inc. | Therapeutic oligonucleotides |
WO2017046140A1 (en) | 2015-09-18 | 2017-03-23 | Bayer Pharma Aktiengesellschaft | Treatment regimens for dr and rvo in dependence of the extent of retinal ischemia |
WO2017161357A1 (en) | 2016-03-18 | 2017-09-21 | Caris Science, Inc. | Oligonucleotide probes and uses thereof |
US11697851B2 (en) | 2016-05-24 | 2023-07-11 | The Regents Of The University Of California | Early ovarian cancer detection diagnostic test based on mRNA isoforms |
AU2017271579B2 (en) | 2016-05-25 | 2023-10-19 | Caris Science, Inc. | Oligonucleotide probes and uses thereof |
EP3332812A1 (en) | 2016-12-07 | 2018-06-13 | Rheinische Friedrich-Wilhelms-Universität Bonn | Nucleic acid-based assembly and use of the assembly in cancer therapy |
TW201904610A (en) | 2017-06-14 | 2019-02-01 | 德商拜耳製藥公司 | Non-antibody vegf antagonists for the treatment of neovascular glaucoma |
TW201906635A (en) | 2017-07-04 | 2019-02-16 | 日商第一三共股份有限公司 | Remedy for retinal degenerative diseases caused by photoreceptor degeneration |
WO2019210097A1 (en) * | 2018-04-25 | 2019-10-31 | Vitrisa Therapeutics, Inc. | Aptamers with stability, potency or half-life for enhanced safety and efficacy |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69008521T2 (en) * | 1989-03-07 | 1994-10-20 | Genentech Inc | COVALENT CONJUGATES OF LIPIDS AND OLIGONUCLEOTIDS. |
US6168778B1 (en) * | 1990-06-11 | 2001-01-02 | Nexstar Pharmaceuticals, Inc. | Vascular endothelial growth factor (VEGF) Nucleic Acid Ligand Complexes |
US5459015A (en) * | 1990-06-11 | 1995-10-17 | Nexstar Pharmaceuticals, Inc. | High-affinity RNA ligands of basic fibroblast growth factor |
US5849479A (en) * | 1990-06-11 | 1998-12-15 | Nexstar Pharmaceuticals, Inc. | High-affinity oligonucleotide ligands to vascular endothelial growth factor (VEGF) |
US5811533A (en) * | 1990-06-11 | 1998-09-22 | Nexstar Pharmaceuticals, Inc. | High-affinity oligonucleotide ligands to vascular endothelial growth factor (VEGF) |
-
1997
- 1997-10-17 ES ES97912811T patent/ES2259188T3/en not_active Expired - Lifetime
- 1997-10-17 NZ NZ334859A patent/NZ334859A/en not_active IP Right Cessation
- 1997-10-17 GE GEAP199711120A patent/GEP20094799B/en unknown
- 1997-10-17 RU RU99110377/04A patent/RU2177950C2/en active
- 1997-10-17 IL IL12949797A patent/IL129497A0/en unknown
- 1997-10-17 DK DK97912811T patent/DK0957929T3/en active
- 1997-10-17 DE DE200612000029 patent/DE122006000029I2/en active Active
- 1997-10-17 JP JP52055398A patent/JP3626503B2/en not_active Expired - Lifetime
- 1997-10-17 AU AU49904/97A patent/AU733674B2/en not_active Expired
- 1997-10-17 AT AT97912811T patent/ATE318143T1/en active
- 1997-10-17 WO PCT/US1997/018944 patent/WO1998018480A1/en active IP Right Grant
- 1997-10-17 DE DE1997635292 patent/DE122006000029I1/en active Pending
- 1997-10-17 EP EP97912811A patent/EP0957929B1/en not_active Expired - Lifetime
- 1997-10-17 EP EP06003279A patent/EP1685842A3/en not_active Withdrawn
- 1997-10-17 PT PT97912811T patent/PT957929E/en unknown
- 1997-10-17 DE DE69735292T patent/DE69735292T2/en not_active Expired - Lifetime
- 1997-10-17 KR KR10-1999-7003488A patent/KR100514929B1/en not_active IP Right Cessation
- 1997-10-17 CA CA002269072A patent/CA2269072C/en not_active Expired - Lifetime
-
1999
- 1999-04-19 IL IL129497A patent/IL129497A/en not_active IP Right Cessation
-
2004
- 2004-10-15 JP JP2004301813A patent/JP4160038B2/en not_active Expired - Lifetime
-
2006
- 2006-06-14 LU LU91252C patent/LU91252I2/en unknown
- 2006-07-03 FR FR06C0021C patent/FR06C0021I2/en active Active
- 2006-07-20 NL NL300234C patent/NL300234I2/en unknown
Also Published As
Publication number | Publication date |
---|---|
DE122006000029I1 (en) | 2006-10-19 |
ES2259188T3 (en) | 2006-09-16 |
DE122006000029I2 (en) | 2007-11-08 |
DK0957929T3 (en) | 2006-07-03 |
JP2001505191A (en) | 2001-04-17 |
JP3626503B2 (en) | 2005-03-09 |
KR100514929B1 (en) | 2005-09-15 |
FR06C0021I1 (en) | 2006-10-13 |
NL300234I1 (en) | 2006-09-01 |
JP2005046160A (en) | 2005-02-24 |
IL129497A (en) | 2009-06-15 |
PT957929E (en) | 2006-06-30 |
NL300234I2 (en) | 2006-10-02 |
DE69735292D1 (en) | 2006-04-27 |
KR20000052697A (en) | 2000-08-25 |
CA2269072A1 (en) | 1998-05-07 |
AU733674B2 (en) | 2001-05-24 |
EP0957929A1 (en) | 1999-11-24 |
RU2177950C2 (en) | 2002-01-10 |
CA2269072C (en) | 2006-02-14 |
IL129497A0 (en) | 2000-02-29 |
GEP20094799B (en) | 2009-10-26 |
NZ334859A (en) | 2001-02-23 |
WO1998018480A1 (en) | 1998-05-07 |
DE69735292T2 (en) | 2006-10-19 |
JP4160038B2 (en) | 2008-10-01 |
EP1685842A3 (en) | 2006-11-29 |
EP0957929A4 (en) | 2003-06-25 |
AU4990497A (en) | 1998-05-22 |
EP0957929B1 (en) | 2006-02-22 |
LU91252I2 (en) | 2006-08-14 |
ATE318143T1 (en) | 2006-03-15 |
EP1685842A2 (en) | 2006-08-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FR06C0021I2 (en) | VASCULAR ENDOTHELIAL GROWTH FACTOR NUCLEIC ACID LIGAND COMPLEXES | |
ATE452136T1 (en) | NUCLEIC ACID LIGAND COMPLEXES | |
DE69109131D1 (en) | METHOD FOR PRODUCING MOLECULAR SCREENS, INCLUDING ZEOLITHES, WITH METAL CHELATE COMPLEXES. | |
DE69002137T2 (en) | MAGNETIC BEARING. | |
GR3008515T3 (en) | ||
DE69017398T2 (en) | Bush mower. | |
DK0705846T3 (en) | High molecular weight and low molecular weight fractions of von Willebrand factor | |
DE59001438D1 (en) | METHOD FOR PRODUCING TETRABROM-4,4'-ALKYLIDEN DIPHENOLS. | |
FI893428A0 (en) | ELIMINERING AV TOXISKA EGENSKAPER IN VITRO OCH IN VIVO HOS TNF-A MEDELST MONOCLONALA ANTIKROPPAR OCH FRAGMENT HAERLEDDA FRAON DESSA. | |
ES2063326T3 (en) | POLYMIXINE CONJUGATES. | |
DE60045577D1 (en) | BY WILLEBRAND FACTOR ACTIVITY NOTICE | |
DE69101708D1 (en) | METHOD FOR PRODUCING TRANSITION METAL NITRIDE COMPLEXES. | |
DK0570575T3 (en) | Bicycloazamacrocyclophosphonic acid, complexes, conjugates, contrast agents and preparation thereof | |
DE59001106D1 (en) | METHOD FOR PRODUCING 1,1,1-TRIFLUOR-2-CHLORETHANE. | |
DE3875512D1 (en) | SCENTED PRODUCT WITH DELIVERY AND METHOD FOR THE PRODUCTION THEREOF. | |
DE68907897T2 (en) | Self-lubricating bearing. | |
DE69012103T2 (en) | METHOD FOR PRODUCING 4,4'-DIISOPROPYLBIPHENYL. | |
IT8720256A0 (en) | B-CYCLODEXTRIN COMPLEXES ANTIFUNGAL ADAPTIVITY. | |
DE59804233D1 (en) | Process for the preparation of formylimidazoles | |
DE59002719D1 (en) | Toroidal core bearing for supporting drive units in motor vehicles. | |
SI0957929T1 (en) | Vascular endothelial growth factor (vegf) nucleic acid ligand complexes | |
IT1256078B (en) | SOLUBLE KIT LIGANDS | |
DE59106957D1 (en) | METHOD FOR PRODUCING TRANS-3,3,5-TRIMETHYLCYCLOHEXYLETHYLETHER. | |
ATE89284T1 (en) | AMINOANTHRACENDIONE BIS PLATINUM COMPLEXES, USEFUL AS ANTITUMORS AGENTS. | |
FI102459B1 (en) | Method for preparing water-soluble silybinine inclusion complexes |